Novartis
NEWS
The companies indicate that the decision was based on lack of efficacy, not any safety concerns.
The agreement revolves around the development and commercialization of Pliant’s preclinical candidate, PLN-1474, and up to three more integrin targets for liver fibrosis associated with nonalcoholic steatohepatitis.
When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.
Last week was busy for clinical trial news. Here’s a look.
The primary endpoint of the trial was improving overall response rate at Day 28 with Jakafi compared to the best available therapy.
It was a busy week for clinical trial announcements. Here’s a look.
What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others?
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
The approval of Beovu was based on findings from the Phase III HAWK and HARRIER clinical trials, in which Novartis’ drug demonstrated non-inferiority versus Eylea in mean change in best-corrected visual acuity at 48 weeks.
JOBS
IN THE PRESS